Alpelisib

Chemical formula: C₁₉H₂₂F₃N₅O₂S  Molecular mass: 441.47 g/mol  PubChem compound: 56649450

Therapeutic indications

Alpelisib is indicated for:

HR-positive, HER2-negative locally advanced or metastatic breast cancer with a PIK3CA mutation

Population group: only adults (18 years old or older)

Alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Alpelisib is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

History of severe cutaneous reactions

Cutaneous hypersensitivity

Osteonecrosis of the jaw caused by bisphosphonate

Bisphosphonate related osteonecrosis of jaw

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2020: PIQRAY Tablet
Summary of Product Characteristics (SPC) 2023: PIQRAY Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈